Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Rallybio (RLYB) EBITDA (2023 - 2025)

Rallybio (RLYB) has disclosed EBITDA for 3 consecutive years, with -$5.9 million as the latest value for Q4 2025.

  • Quarterly EBITDA rose 47.44% to -$5.9 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$9.0 million through Dec 2025, up 84.36% year-over-year, with the annual reading at -$9.0 million for FY2025, 84.36% up from the prior year.
  • EBITDA hit -$5.9 million in Q4 2025 for Rallybio, down from $16.0 million in the prior quarter.
  • In the past five years, EBITDA ranged from a high of $16.0 million in Q3 2025 to a low of -$20.0 million in Q4 2023.
  • Historically, EBITDA has averaged -$11.8 million across 3 years, with a median of -$13.7 million in 2024.
  • Biggest five-year swings in EBITDA: fell 11.36% in 2024 and later surged 242.73% in 2025.
  • Year by year, EBITDA stood at -$20.0 million in 2023, then skyrocketed by 44.33% to -$11.1 million in 2024, then soared by 47.44% to -$5.9 million in 2025.
  • Business Quant data shows EBITDA for RLYB at -$5.9 million in Q4 2025, $16.0 million in Q3 2025, and -$9.7 million in Q2 2025.